Navigation Links
Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 27, 2007 - Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced positive results from a recently-completed multi-dose pharmacokinetic study of vaginally-administered lidocaine, which the Company is developing to prevent and treat dysmenorrhea.

This 42-subject study was designed to provide data on blood levels associated with the Company's bioadhesive vaginal lidocaine formulation at three dose strengths over multiple doses. The cohort was randomly divided into three groups, which corresponded to the three different dose strengths of the lidocaine product candidate.

"For each of the dose levels studied, use of our bioadhesive vaginal lidocaine formulation over four consecutive days was associated with blood levels that are well within an accepted range," stated George Creasy, M.D., FACOG, Columbia's vice president of clinical research and development. "At the highest dose, those blood levels are what we anticipated based on extrapolation of data from the prior, single-administration pharmacokinetic study. This indicates a positive safety profile for our lidocaine product candidate relative to the known systemic effects of lidocaine."

"This positive data strengthens our resolve to speed the path to market for our lidocaine product. We received approval from the Institutional Review Board to conduct a Phase II cross-over study with this drug candidate and we will begin recruiting patients in this study very soon," stated Robert S. Mills, president and chief executive officer of Columbia Laboratories. "There are approximately 5.6 million women who suffer from the painful menstrual cramping that characterizes dysmenorrhea, which limits their normal activities and causes them to lose time from school or work. We believe our lidocaine product can fill a real unmet medical need and improve the lives of these women, assuming positive data in current and future c
'"/>




Page: 1 2 3

Related medicine technology :

1. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
2. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
3. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
5. Northfield Laboratories Investor Update
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:7/23/2014)... MEETING, Pa. , July 23, 2014 ... INO) today announced successful results from its ... VGX-3100 in women with biopsy-proven cervical intraepithelial ... (HPV) types 16 or 18. Treatment with ... regression of CIN2/3 to CIN1 or no ...
(Date:7/23/2014)... 23, 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: ... on its expertise in opioid antagonists, announced today ... application ("IND") with respect to its naloxone-based opioid ... that it has received an additional commitment from ... of the National Institutes of Health ("NIH"), to ...
(Date:7/23/2014)... Calif. , July 23, 2014  Cardica, Inc. (Nasdaq: ... financial results for its fiscal fourth quarter and year ended ... markets close. Cardica,s management will host a conference call at ... provide an update on the company,s business. Conference ... 7, 2014, at 4:30 p.m. Eastern Time via phone, please ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2
(Date:7/23/2014)... 23, 2014 In preparation for National ... Millennium Treatment Group is providing tips on choosing a ... society ever since man first figured out the process ... has existed since shortly thereafter. Its basis lies in ... then developing a way to combat that problem while ...
(Date:7/23/2014)... If past experience is anything to go by, ... get a lot more recognition for their contributions to ... allowing NPs to provide primary care offer nurses more ... relationships with physicians and administrators, compared with colleagues in ... School of Nursing, published in Health Care Management ...
(Date:7/23/2014)... Asking patients if a suspicious skin lesion is painful ... is likely to be cancerous, according to a new ... Department of Dermatology at Temple University School of Medicine. ... on July 23, 2014, found that nearly 36. ... itching, while 28.2 percent involve pain. Non-melanoma skin cancers ...
(Date:7/23/2014)... 23, 2014 Home Care Assistance ... for seniors, is proud to announce the next installment ... in a wide range of health and wellness-related fields. ... and award-winning author Nancy Kriseman, and will cover the ... prevent burnout by becoming more self-aware. In particular, Nancy ...
(Date:7/23/2014)... News) -- Regularly checking the pulse of a stroke ... "Screening pulse is the method of choice for checking ... have never had a stroke. Our study shows it ... to identify people who might need more thorough monitoring ... Bernd Kallmunzer, of Erlangen University in Germany. ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:New York law offers nurses more recognition, responsibility 2Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2
... www.ibsfl.com ) is proud to announce the recent ... business services, providing advanced technology support services in ... has over 40 employees serving the greater Tampa ... IBS services include IT Consulting and Strategy management, ...
... Measures Helping Those Suffering,from Mental Illness, ARLINGTON, Va., ... someone with a severe mental illness in Louisiana to ... on,June 21, 2008. The law, which unanimously passed both ... effect on August 15., "Nicola,s Law," named after ...
... 8 Healthation, a healthcare,technology company, today ... Software,as a Service agreement with Health Partners, ... members in southeastern Pennsylvania. Health,Partners will implement ... deliver interactive, real-time communication and,administration capabilities to ...
... a U.S. House,Government Oversight Subcommittee Hearing today, a ... mercury pollution by phasing out amalgam,requiring dentists to ... for paying for the clean up technology necessary ... age of amalgam is over," said Michael,Bender, director ...
... is one of the most complex and challenging mental ... with considerable acute and longterm treatment needs and may ... of tremendous social burden for both the individual and ... yet lifelong and clinically severe mood disorder. The disorder ...
... July 8 Kewaunee Scientific,Corporation (Nasdaq: KEQU ... the Russell,Microcap Index after the Russell Investment Group ... indexes on June 27, 2008., Russell indexes ... for both index funds and as benchmarks for ...
Cached Medicine News:Health News:Infinity Business Systems of Tampa Expands Into Sarasota / Bradenton 2Health News:Infinity Business Systems of Tampa Expands Into Sarasota / Bradenton 3Health News:Louisiana Improves Law for Treating Mentally Ill 2Health News:Health Partners Chooses Healthation's AboveHealth Provider Portal 2Health News:Congress Called on to Hold Dental Mercury Polluters Accountable at U.S. House Oversight Hearing 2Health News:The ECNP consensus statement on bipolar depression 2Health News:Kewaunee Scientific Added to Russell Microcap Index 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: